Abstract
A patient with a potassium wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome is described. A 64-year-old woman with diffuse histiocytic lymphoma developed persistent hypokalemia following a course of Cytoxan (cyclophosphamide), Adriamycin (doxorubicin), vincristine, and prednisone (CHOP)-Bleo. The diagnosis of a functional Bartter's syndrome was concluded following evaluation of serial plasma renins, aldosterone levels, and urinary electrolytes. Evidence is suggestive that a subpopulation of patients receiving chemotherapy may develop a functional Bartter's syndrome, and it is important to consider this diagnosis in patients who develop hypokalemia subsequent to chemotherapy introduction.
MeSH terms
-
Aldosterone / blood
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bartter Syndrome / blood
-
Bartter Syndrome / chemically induced*
-
Bartter Syndrome / urine
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Diagnosis, Differential
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Female
-
Humans
-
Hyperaldosteronism / chemically induced*
-
Hypokalemia / blood
-
Hypokalemia / chemically induced*
-
Hypokalemia / urine
-
Lymphoma, Large B-Cell, Diffuse / blood
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / urine
-
Magnesium / urine
-
Middle Aged
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Renin / blood
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Bleomycin
-
Aldosterone
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Renin
-
Magnesium
-
Prednisone